Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
50 hedge funds and large institutions have $184M invested in Agile Therapeutics in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 6 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
22% more capital invested
Capital invested by funds: $151M → $184M (+$33.2M)
4% more funds holding
Funds holding: 48 → 50 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$2.31M |
| 2 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$1.04M |
| 3 |
RA
Royce & Associates
New York
|
+$561K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$301K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$288K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aisling Capital
New York
|
-$2.74M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.44M |
| 3 |
SCM
Sio Capital Management
New York
|
-$1.03M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$822K |
| 5 |
JGC
J. Goldman & Co
New York
|
-$370K |
AGRX Hedge Fund Activity: Q2 2016 in Review
50 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q2 2016, worth a combined $184M — up 22% from $151M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new AGRX positions and 6 closed out — a net gain of 2 holders — while 17 added to existing stakes and 11 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $2.31M. The largest seller was Aisling Capital, cutting an estimated $2.74M.
- 50 institutional investors held Agile Therapeutics (AGRX) as of Q2 2016, up from 48 in Q1 2016.
- Funds reported $184M of Agile Therapeutics stock for Q2 2016, up 22% quarter-over-quarter.
- 8 funds opened new Agile Therapeutics positions in Q2 2016 and 6 closed out, a net change of +2 holders.
- The largest Agile Therapeutics buyer in Q2 2016 was Perceptive Advisors, an estimated $2.31M added.
- The largest Agile Therapeutics seller in Q2 2016 was Aisling Capital, an estimated $2.74M sold.
Based on aggregated 13F filings for Q2 2016.